Codexis is a biotechnology company that develops biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its CodeEvolver platform to engineer enzymes for various applications.

Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins.

Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Innovatus Capital Partners

Casdin Capital

Maxygen

Chevron Technology Ventures

Pequot Capital

EDBI

CMEA Capital

Codexis, Inc.

We see incredible potential for enzymatic synthesis to support RNAi therapeutics manufacturing. 

To learn more, check out the interview our COO Kevin Norrett did with Genetic Engineering & Biotechnology News following our groundbreaking #TIDESUSA presentation last month.

#proteinengineering #enzymeengineering #RNAi

Join our SVP of Research Stefan Lutz for a panel discussion on scaling RNA therapies and a presentation by Mathew Miller discussing the cost effectiveness of manufacturing siRNA duplexes with engineered dsRNA ligases at RNA Leaders next week.

Several Codexians will be on the ground in San Diego for the conference. Message us here to set up a meeting with our team or stop by Booth #9 for an impromptu chat.

Safe travels to everyone heading to San Diego ✈️ and we'll see you there!

#RNALeaders #enzymeengineering #proteinengineering #RNAitherapeutics

Stefan, Matt, Kevin Norrett, Britton Jimenez, Mark Hochstetler and Jean Shieh - have a great meeting!

Who is joining us in San Diego for #RNALeaders?

Meet up with our Codexis team on the ground or join us for one of our two presentations on enzymatic synthesis for RNAi therapeutics.

Hit the follow button for more info on our presence at RNA Leaders and our market-leading enzymatic synthesis capabilities.

#proteinengineering #enzymeengineering #RNAitherapeutics

We're excited to share that today we issued our initial ESG disclosures aligned with the Sustainability Accounting Standards Board.

You can read more in our press release: https://bit.ly/4dmXLAs

#sustainability #ESG #governance #RNAitherapeutics

Today we issued our Q2 2024 financial results and provided a business update. 

Click below to read our press release and listen to our investor call beginning at 4:30 pm ET.

Link: https://bit.ly/3LYGn8U 

#codexis #proteinengineering #enzymeenginering #rnaitherapeutics

We are excited to be attending and sponsoring the RNA Leaders Conference next month in San Diego!

We'll have an entire team on the ground ready to chat all about our enzymatic synthesis capabilities. 

Want to meet up? Stop by Booth #9 or message us here to make an appointment. 

#RNALeaders #Codexis #proteinengineering #enzymeengineering #rnaitherapeutics

Codexis is reporting Q2 2024 financial results and providing a business update on Thursday, August 8th! 

Read our press release for all the details: https://lnkd.in/ef9B2HZr

Following our groundbreaking #TIDESUSA presentation last month, Codexis Chief Operating Officer Kevin Norrett had a virtual sit down with Genetic Engineering & Biotechnology News to discuss RNAi therapeutics manufacturing.

The resulting feature article highlights the need and urgency for another option to supplement traditional chemical manufacturing practices, which will face challenges of scale as more RNAi therapeutics make their way through the development process...there are of 450 of them in clinical trials right now!

Click the link below for the full article discussing enzymatic synthesis for RNAi therapeutics.

Link: https://lnkd.in/ej2uGzFc

#proteinengineering #enzymeengineering #RNAitherapeutics #RNAi

Each quarter we host an activity that supports our Community corporate value.

Sometimes this about our internal community as Codexians and strengthening our corporate culture.

Other times, it's about supporting the local communities in which we work and live.

Last week, we were thrilled to assemble 250 backpacks for rising kindergarten to 2nd grade students in our local community with the help of Family Giving Tree.

The team at FGT set up a brilliant assembly line in our Boardroom and we had everything packed in about 90 minutes! We laughed, we bumped into each other, we smiled and then we said we wish we had more to do.

If you're looking for a teambuilding activity in the Bay Area, definitely give L. Margarita Galindo MNA at FGT a call.

Huge thanks to Vesna Mitchell, Michael Whitehorn and the Codexis Activities Committee for bringing this opportunity to us! 

#giveback #communityrelations #proteinengineering #enzymeengineering #rnai #RNAitherapeutics

It's the last day of #TIDESUSA!

The Codexis crew is ready to talk all things enzyme engineering, ligation and RNAi therapeutics. Stop by Booth #628 to say hi and learn more!

#proteinengineering #enzymeengineering #RNAi #RNAitherapeutics #ligase

DNSSEC

IPv6

ASP.NET

IIS 10

Amazon S3

Microsoft

Google Adsense

Microsoft Azure

Apple Whitelist

Company Owner

Jennifer Wagner

President & Chief Executive Officer

John Nicols

Chief Operating Officer

Kevin Norrett

Board Director

Pat Yang

SVP & CFO

Ross Taylor

VP and Head of Corporate Development

Asli Aras

Chief Executive Officer

Gjalt Huisman

Senior Vice President & Head of Human Resources

Karen Frechou-Armijo

SVP Development & Operations

Karl A. Schoene

Vice President Information Technology

Michael Vedda

Dennis Wolf

Georgia Erbez

Margaret Fitzgerald

Chief Legal & Compliance Officer, General Counsel

VP & Head of Corporate Development

Aaron Hammons

Senior Director of Business Development, Americas

Rob Wilson

SVP & General Manager, Performance Enzymes

Stephen Dilly

President, CEO and Board member

SVP & Head of Human Resources

San Francisco Bay Area Companies With More Than 50 Employees (Top 10K)

Investors Active in United States (Top 10K)

Biotechnology Companies (Top 10K)

Sustainability Companies With More Than $1M in Revenue

Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development.
Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.
Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA

Post-IPO Debt - Codexis

Post-IPO Equity - Codexis

Series D - Codexis

Redwood City

California

United States

North America

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Codexis Announces New Employment Inducement Grants

Codexis to Participate in Upcoming Healthcare Conferences

Codexis increases cash reserves; appoints Georgia Erbez as CFO (NASDAQ:CDXS)

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Codexis licenses Genomics Life Science enzyme portfolio to Alphazyme LLC

A proprietary technology platform used to discover, develop, and enhance novel enzymes and proteins for various applications.

A manufacturing platform designed to enable the scaled production of RNAi therapeutics through enzymatic synthesis.

Custom enzymes developed to improve the manufacturing processes of small molecule pharmaceuticals.

Services that enhance traditional RNA synthesis by optimizing the ligation of RNA strands.

Services focused on producing RNA for therapeutic applications with high yield and minimal byproducts.

India

Asia

Israel

Hong Kong

Philippines

HTML5

Lightbox

Google Analytics

HubSpot Marketing Hub

F5 NGINX

Google Fonts

Fonts.com

Google Doubleclick

Google Tag Manager

Google Drive

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

news impact assignment basic	general
public peers	general	Sep 3, 2024 12:50 PM	55032c22
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 3:52 PM	44814cc7
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	3498c293
crunchbase profile	general	Nov 22, 2024 3:09 PM	3ef478ec
li profile	general	Sep 3, 2024 12:50 PM	bc64446c
translate crunchbase fundingrounds	general	Nov 22, 2024 8:38 PM	e0e0c51a
peers	general	Sep 3, 2024 12:50 PM	a45729fb
news basic	general	Sep 3, 2024 12:50 PM	23ae3337
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CODEXIS

Codexis

Last Close

4.33

22/11 21:00

Market Cap

204.62M

Beta: -

Volume Today

700.76K

Avg: -